Abstract：
The use of octreotide in managing intrathoracic chyle leak following esophagectomy has gained popularity in the adult population. While the benefits of octreotide have been confirmed in the pediatric population, there remains limited evidence to support its use in the adults post-esophagectomy. Thus, we performed a single-institution cohort study to characterize its efficacy. The study was performed using a prospective, single-center database, from which clinicopathologic characteristics were extracted of patients who had post-esophagectomy chyle leaks. Kaplan-Meier and multivariable Cox regression analyses were performed to investigate the effect of octreotide use on chest tube duration (CTD), hospital length of stay (LOS), and overall survival (OS). In our cohort, 74 patients met inclusion criteria, among whom 27 (36.5%) received octreotide. Kaplan-Meier revealed no significant effect of octreotide on CTD (P = 0.890), LOS (P = 0.740), or OS (P = 0.570). Multivariable Cox regression analyses further corroborated that octreotide had no effect on CTD (HR = 0.62, 95% confidence interval [CI]: 0.32-1.20, P = 0.155), LOS (HR = 0.64, CI: 0.34-1.21, P = 0.168), or OS (1.08, CI: 0.53-2.19, P = 0.833). Octreotide use in adult patients with chyle leak following esophagectomy lacks evidence of association with meaningful clinical outcomes. Level 1 evidence is needed prior to further consideration in this population.
摘要：
在成人人群中，使用奥曲肽治疗食道切除术后的胸内乳糜漏已越来越受欢迎。虽然奥曲肽的益处已在儿科人群中得到证实，目前仍有有限的证据支持其在成人食管切除术后使用.因此，我们进行了一项单机构队列研究,以确定其疗效.这项研究是使用前瞻性的，单中心数据库，从中提取了食管癌切除术后乳糜漏患者的临床病理特征。进行了Kaplan-Meier和多变量Cox回归分析，以研究使用奥曲肽对胸管持续时间（CTD）的影响，住院时间（LOS），总生存率（OS）。在我们的队列中，74例患者符合纳入标准，其中27人(36.5%)接受奥曲肽治疗。Kaplan-Meier显示奥曲肽对CTD无显著影响(P=0.890),LOS（P=0.740），或OS(P=0.570)。多变量Cox回归分析进一步证实奥曲肽对CTD无影响(HR=0.62,95%置信区间[CI]:0.32-1.20,P=0.155),LOS（HR=0.64，CI：0.34-1.21，P=0.168），或OS（1.08，CI：0.53-2.19，P=0.833）。食道切除术后乳糜漏的成年患者使用奥曲肽缺乏与有意义的临床结局相关的证据。在进一步考虑该人群之前，需要1级证据。
